The prediction of papaverine induced priapism by color Doppler sonography.
OBJECTIVE
We identified color Doppler sonography findings that are useful for predicting priapism in patients after the intracavernous injection of diagnostic papaverine.


METHODS
We evaluated 72 men with erectile dysfunction by color Doppler sonography after the diagnostic injection of papaverine. Cavernous artery waveforms were recorded, and peak systolic and diastolic velocity of the recorded waveforms was measured. In cases of priapism color Doppler sonography findings were retrospectively evaluated to identify any finding that would predict priapism.


RESULTS
Priapism was observed in 8 of the 72 patients (11.1%). In 6 of 8 priapism cases there was no blood flow in the cavernous artery during or after adequate erection, including after minutes 5, 10 and 20 in 3, 1 and 2, respectively. This absence of encoding was not relieved even after all stimuli were removed. In 2 patients who later presented with complaints of priapism the Doppler study was completed normally and all parameters were acquired without any cessation of blood flow in the cavernous artery. The persistent disappearance of color and pulse encoding in the cavernous artery predicted priapism with 75% sensitivity, 100% specificity, a positive and negative predictive value of 100% and 96.9%, respectively, and 97% accuracy.


CONCLUSIONS
The persistence of absent blood flow in the cavernous artery even after the elimination of all stimuli during penile color Doppler ultrasound is a reliable predictor of priapism. The finding is accurate enough to initiate treatment for priapism to avoid further delay.
Secil
M
M
Departments of Radiology and Urology, Dokuz Eylul University Hospital, Izmir, Turkey.
Arslan
D
D
Goktay
A Y
AY
Esen
A A
AA
Dicle
O
O
Pirnar
T
T
D006801:Humans; D008297:Male; D010208:Papaverine / Q000009:adverse effects*; D011237:Predictive Value of Tests; D011317:Priapism / Q000139:chemically induced*; D012189:Retrospective Studies; D018615:Ultrasonography, Doppler, Color; D014665:Vasodilator Agents / Q000009:adverse effects*
D014665:Vasodilator Agents; D010208:Papaverine